Comparing an Interferon Gamma Release Assay with the Tuberculin Skin Test During Pregnancy: Implications for XXXX Screening During Prenatal Care.

@entity1 @entity9178 @entity1906 @entity272 @entity378
UNASSIGNED: Background Currently there are no guidelines regarding optimal screening for @entity9178 during pregnancy. Objective This study measures completion rates and the concordance between the TSPOT. @entity1906 , a commercially available interferon gamma release assay (IGRA), and the traditional @entity272 ( @entity272 ) in a predominantly urban minority obstetrics practice. Design This is an observational cohort study of 141 pregnant @entity1 enrolled from an obstetrics practice with a large immigrant population. @entity1 with a history of a positive @entity272 result were excluded. Demographic and clinical risk factors for @entity378 were assessed. Enrolled @entity1 underwent a T-SPOT. @entity1906 test and placement of @entity272 , and returned in 48-72  h for @entity272 interpretation. We calculated the completion rate and frequency of a positive result for each test, as well as the concordance between the T-SPOT. @entity1906 and @entity272 . Results Among the 141 @entity1 enrolled, 75  % were either Latina or African-American, 44  % were born in a country with a high @entity1906 prevalence, and 52  % had received the Bacillus Calmette-Guerin vaccine. Seven @entity1 (5  %) had a positive screening test, a total of 3 positive T-SPOT. @entity1906 results and 6 positive @entity272 results, and all were from countries with a high @entity1906 prevalence. The concordance of the two tests was 96.3  %. The completion rate for the T-SPOT. @entity1906 was 98  %, while the completion rate for the @entity272 was 63  %. CONCLUSION: The IGRA test had a markedly higher completion rate in addition to maintaining high concordance with the two-step @entity272 in this population of pregnant @entity1 with a high prevalence of prior @entity1906 exposure. Targeted screening of @entity1 from countries with a high prevalence of @entity378 may be warranted during prenatal care.
